Characteristics and treatment strategies for small bowel adenocarcinoma in advanced-stage cases

Tomonori Nakanoko, Tadashi Koga, Kenji Taketani, Yoshie Hirayama, Shohei Yoshiya, Ryosuke Minagawa, Masanori Kai, Kiyoshi Kajiyama, Yoshihiko Maehara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Small bowel adenocarcinoma is an uncommon disease with poor prognosis. Therefore, characteristics and treatment strategies for small bowel adenocarcinoma should be elucidated sufficiently, not only for surgery, but also for chemotherapy. Patients and Methods: Medical records were abstracted to identify patients with small bowel adenocarcinoma who were treated at the Iizuka Hospital, Fukuoka, Japan, between 2004 and 2014. The results of surgical treatment for stage II/III cases and the efficacy of chemotherapy for unresectable stage IV cases were investigated. Results: The median tumor size was 25.6±19.2 mm, and tumor size was not associated with primary symptoms. Nine of the patients were diagnosed with stage II/III disease and underwent surgical resection. The other three patients were diagnosed with stage IV disease, and two out of those three cases received definitive chemotherapy. In two out of the nine resected cases, recurrence was observed; however, surgical resection of the recurrent tumor was associated with a good prognosis. In stage IV cases that received chemotherapy, survival durations of over 11 months were achieved. In contrast, overall survival in the stage IV case without chemotherapy was 3.3 months. Conclusion: Curative resection and definitive chemotherapy for unresectable cases are effective treatment strategies for small bowel adenocarcinoma.

Original languageEnglish
Pages (from-to)4135-4138
Number of pages4
JournalAnticancer research
Volume35
Issue number7
Publication statusPublished - Jul 1 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Characteristics and treatment strategies for small bowel adenocarcinoma in advanced-stage cases'. Together they form a unique fingerprint.

Cite this